Telix Pharmaceuticals Limited (ASX:TLX)
Australia · Delayed Price · Currency is AUD 16.09
+0.51 (3.27%)
Aug 28, 2026, 10:24 AM AEST
Telix Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 890.79 | 803.79 | 516.55 | 332.98 | 108.81 | 5.52 | |
Revenue Growth | 33.49% | 55.61% | 55.13% | 206.01% | 1870.12% | 37.33% |
Cost of Revenue | 467.08 | 421.95 | 197.06 | 129.7 | 44.29 | 1.85 |
Gross Profit | 423.71 | 381.85 | 319.49 | 203.28 | 64.52 | 3.67 |
Selling, General & Admin | 202.88 | 192.56 | 135.52 | 83.13 | 59.2 | 34.16 |
Research & Development | 213.49 | 171.25 | 127.93 | 85.32 | 55.06 | 24.82 |
Other Operating Expenses | -47.93 | -1.25 | 0.16 | -0.14 | 0.63 | - |
Operating Expenses | 368.45 | 362.56 | 263.61 | 168.3 | 114.89 | 62.75 |
Operating Income | 55.26 | 19.29 | 55.88 | 34.98 | -50.37 | -59.08 |
Interest Expense | -14.99 | -13.76 | -4.79 | -0.52 | -0.22 | -0.12 |
Interest & Investment Income | 4.48 | 5.83 | 7.18 | 0.67 | 0 | - |
Currency Exchange Gain (Loss) | -0.56 | -0.56 | 11.9 | -0.73 | -0.76 | 1.23 |
Other Non Operating Income (Expenses) | -29.36 | -27.11 | -19.65 | -8.57 | -4.33 | 10.25 |
EBT Excluding Unusual Items | 14.83 | -16.32 | 50.52 | 25.83 | -55.68 | -47.71 |
Merger & Restructuring Charges | - | - | -5.75 | - | - | - |
Asset Writedown | -0.57 | -0.57 | 0.48 | -0.55 | - | - |
Other Unusual Items | 14.55 | 11.62 | -7.33 | -22.69 | -11.36 | -10.8 |
Pretax Income | 28.82 | -5.27 | 37.92 | 2.59 | -67.03 | -58.51 |
Income Tax Expense | -4.68 | 1.86 | 4.23 | -1.61 | 3.71 | 0.03 |
Net Income | 33.5 | -7.13 | 33.69 | 4.21 | -70.74 | -58.54 |
Net Income to Common | 33.5 | -7.13 | 33.69 | 4.21 | -70.74 | -58.54 |
Net Income Growth | 183.82% | - | 700.50% | - | - | - |
Shares Outstanding (Basic) | 342 | 338 | 331 | 319 | 311 | 282 |
Shares Outstanding (Diluted) | 351 | 338 | 345 | 324 | 311 | 282 |
Shares Change | 2.75% | -2.12% | 6.64% | 4.21% | 10.08% | 9.69% |
EPS (Basic) | 0.10 | -0.02 | 0.10 | 0.01 | -0.23 | -0.21 |
EPS (Diluted) | 0.10 | -0.02 | 0.10 | 0.01 | -0.23 | -0.21 |
EPS Growth | 174.82% | - | 650.77% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -45.49 | -42.99 | 18.37 | 7.97 | -48.26 | -44.11 |
Free Cash Flow Per Share | -0.13 | -0.13 | 0.05 | 0.03 | -0.15 | -0.16 |
Gross Margin | 47.57% | 47.50% | 61.85% | 61.05% | 59.29% | 66.46% |
Operating Margin | 6.20% | 2.40% | 10.82% | 10.51% | -46.29% | -1069.60% |
Profit Margin | 3.76% | -0.89% | 6.52% | 1.26% | -65.01% | -1059.90% |
Free Cash Flow Margin | -5.11% | -5.35% | 3.56% | 2.39% | -44.35% | -798.67% |
EBITDA | 69.81 | 32.46 | 59.64 | 38.17 | -47.3 | -55.79 |
EBITDA Margin | 7.84% | 4.04% | 11.54% | 11.46% | -43.47% | - |
D&A For EBITDA | 14.55 | 13.17 | 3.75 | 3.19 | 3.07 | 3.29 |
EBIT | 55.26 | 19.29 | 55.88 | 34.98 | -50.37 | -59.08 |
EBIT Margin | 6.20% | 2.40% | 10.82% | 10.51% | -46.29% | - |
Effective Tax Rate | - | - | 11.16% | - | - | - |